1. Center for Disease Control and Prevention (CDC), 2015. West Nile Virus. Available at: 〈www.cdc.gov/westnile/index.html〉 (accessed 28.04.15).
2. Chaves, C., Ganguly, R., Dionne, C., et al., 2014. Safety and efficacy of dimethyl fumarate in patients with relapsing remitting MS (RRMS) in a community setting. Presented at the 2014 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and the Sixth Cooperative Meeting with Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS). Dallas, TX (Abstract DX22)
3. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis;Fox;New Engl. J. Med.,2012
4. Fox, R.J., Gold, R., Phillips, J.T., et al., 2014. Lymphocyte count reductions in relapsing-remitting multiple sclerosis (RRMS) patients treated with delayed-release dimethyl fumarate: an integrated analysis of the placebo-controlled studies. Presented at the 66th Annual Meeting of the American Academy of Neurology. April 26–May 3, 2014
5. Dimethyl fumarate associated lymphopenia in clinical practice;Longbrake;Mult Scler.,2015